{
  "meta": {
    "title": "Menstrual_Physiology_Premenstrual_Syndromes_Dysmenorrhea_Menopause_Hrt",
    "url": "https://brainandscalpel.vercel.app/menstrual-physiology-premenstrual-syndromes-dysmenorrhea-menopause-hrt-6b294fca.html",
    "scrapedAt": "2025-11-30T11:17:43.580Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased Progesterone</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased Estrogen</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased FSH</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased Androgens</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In the ovarian cycle, increased levels of LH are due to:</span></p>",
      "unique_key": "DT1188803",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188803,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>During the <strong>mid-cycle phase of the ovarian cycle</strong>, a <strong>dramatic rise in estradiol (a potent estrogen)</strong> leads to <strong>positive feedback on the hypothalamic-pituitary axis</strong>, which triggers a <strong>sudden surge in LH levels</strong>.</li>\n<li>Initially, low levels of estrogen exert <strong>negative feedback</strong>, suppressing LH secretion. However, once <strong>estradiol levels exceed approximately 200 pg/mL</strong>, the feedback switches to positive.</li>\n<li>This <strong>positive feedback</strong> results in the <strong>bio-ovulatory LH surge</strong>, which is essential for <strong>ovulation</strong>.</li>\n<li>This surge also enhances <strong>FSH secretion</strong>, but the <strong>LH rise is more significant</strong>, increasing nearly <strong>10-fold</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Increased Progesterone (Option A):</strong> Progesterone levels rise after ovulation (in the luteal phase) and are not responsible for the LH surge.</p>\n<p><strong>Increased FSH (Option C): </strong>FSH rises during the early follicular phase but does not cause the LH surge.</p>\n<p><strong>Increased Androgens (Option D):</strong> Androgens play no direct role in triggering the mid-cycle LH surge.<br /> </p>",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Also called RU-486</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">It is a 19-nor steroid</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Acts on progesterone receptors</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Given only intravenously</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not true about mifepristone?</span></p>",
      "unique_key": "DT1188864",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188864,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>RU 486 (Mifepristone)</strong> is a <strong>19-nor steroid synthetic derivative of progesterone</strong>. It has an affinity for <strong>progesterone receptors </strong>and therefore blocks its actions. <strong>(Option A, B and C)</strong></li>\n<li><strong>Route of administration: Oral.</strong></li>\n</ul>\n<p><strong>Uses</strong>:</p>\n<ul>\n<li>As a post-coital pill (600 mg given within 72 hours of unprotected sex).</li>\n<li>To induce abortion up to 7 weeks of amenorrhea, along with misoprostol (medical abortion).</li>\n<li>Ripening of the cervix before prostaglandin induction of mid-trimester abortion.</li>\n<li>Management of ectopic pregnancy.</li>\n<li>Cushing's syndrome: because of its antiglucocorticoid action.</li>\n<li>Medical management of uterine fibroids.</li>\n</ul>\n<p><strong>Side effects</strong>:</p>\n<ul>\n<li>Headache</li>\n<li>GI upset</li>\n<li>Adrenal failure</li>\n<li>Teratogenicity (If medical methods of abortion fail with RU-486, pregnancy should be terminated anyhow).</li>\n</ul>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Non-steroidal water-soluble protein</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Secreted by the Graafian follicle</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Stimulates FSH secretion</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased secretion of inhibin occurs in polycystic ovarian disease</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All are the features of inhibin except:-</span></p>",
      "unique_key": "DT1188867",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188867,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Inhibin suppresses FSH secretion.</strong> It doesn't stimulate FSH secretion.</li>\n<li>Inhibin is a <strong>non-steroidal, water-soluble protein. (Option A)</strong></li>\n<li>Inhibin is indeed <strong>secreted by the Graafian follicle</strong> in females and the Sertoli cells in males. <strong>(Option B)</strong></li>\n<li>It is of two types - Inhibin A and B. In the early and mid-follicular phase, inhibin B is the predominant form secreted, whereas inhibin A begins to rise in the late follicular phase to reach a peak in the mid-luteal phase.</li>\n<li><strong>In PCOS, inhibin secretion increases. (Option D)</strong></li>\n</ul>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Follicular development and differentiation take about 85 days</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">AMH supports mono-follicular development</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">The first phase of follicular growth is gonadotropin-insensitive</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Elevated and static levels of estradiol are essential for ovulation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All are true regarding folliculogenesis and ovulation except:</span></p>",
      "unique_key": "DT1188873",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188873,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>For ovulation to occur, <strong>not static but rapidly rising (dynamic) levels of estradiol</strong> are required to generate the positive feedback necessary for the <strong>LH surge</strong>. Constant or static estradiol levels will <strong>not</strong> trigger ovulation.</li>\n<li>The development of a <strong>cohort of growing follicles</strong> takes approximately <strong>85 days</strong>, spanning <strong>three menstrual cycles,</strong> before one dominant follicle is selected for ovulation. <strong>(Option A)</strong></li>\n<li><strong>Anti-Mullerian Hormone (AMH)</strong> limits the initial recruitment of follicles and supports <strong>mono-follicular selection</strong>, thereby preventing excessive follicular development. <strong>(Option B)</strong></li>\n<li>The <strong>initial recruitment and growth of primordial follicles</strong> occur <strong>independently of gonadotropins</strong> (FSH/LH). Gonadotropin sensitivity appears later when follicles reach 2-5 mm in size. <strong>(Option C)</strong></li>\n</ul>",
      "correct_choice_id": 34,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Progesterone effect</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Estrogenic effect</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Effect of LH</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Eosinophilic index or Cornification index indicates:</span></p>",
      "unique_key": "DT1188876",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188876,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The <strong>eosinophilic index</strong> or cornification index is a measure used in cytology, particularly in 47 assessing vaginal smears.</li>\n<li>It indicates the <strong>level of maturation</strong> and <strong>cornification</strong> of the cells lining the vaginal epithelium.</li>\n<li>This is primarily influenced by <strong>estrogen, so it reflects the estrogenic effect on the cells.</strong></li>\n</ul>\n<p><strong>Explanation of other options</strong>:-</p>\n<p><strong>Progesterone effect (Option A):</strong> Progesterone leads to desquamation and shedding of superficial cells rather than cornification.</p>\n<p><strong>Effect of LH (Option C):</strong> LH primarily regulates ovulation and has no direct role in vaginal epithelial maturation or cornification.</p>",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Alkaline phosphatase</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Aromatase</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Acid phosphatase</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Glucuronidase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Granulosa cells produce estrogen with the help of the enzyme:</span></p>",
      "unique_key": "DT1188878",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188878,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The granulosa cells play a vital role in <strong>estrogen production</strong> in the ovary.</li>\n<li>The theca cells initially produce androgens (mainly androstenedione).</li>\n<li>These androgens then diffuse into the granulosa cells, where they are converted into estrogens (primarily estradiol, E2) by the <strong>enzyme aromatase.</strong></li>\n<li><strong>Aromatase is the key enzyme that catalyses the conversion of androgens to estrogens in granulosa cells.</strong></li>\n<li>This conversion is crucial for follicular development and endometrial proliferation.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Alkaline phosphatase (Option A): </strong>This enzyme is not involved in estrogen synthesis. It is associated with bone formation and other tissues, but not with steroidogenesis.</p>\n<p><strong>Acid phosphatase (Option C):</strong> Acid phosphatase is primarily linked to the prostate gland and lysosomal activity. It has no role in estrogen production.</p>\n<p><strong>Glucuronidase (Option D):</strong> This enzyme is involved in carbohydrate metabolism and not in the steroid hormone synthesis pathway.</p>",
      "correct_choice_id": 52,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Bone marrow depression</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperstimulation syndrome</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Secondary amenorrhea</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiple pregnancy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The most serious complication of clomiphene therapy for the induction of ovulation is:</span></p>",
      "unique_key": "DT1188885",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188885,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Ovarian Hyperstimulation Syndrome (OHSS)</strong> arises from the administration of <strong>exogenous gonadotropins or ovulation induction drugs like clomiphene citrate.</strong></li>\n<li>Following gonadotropin stimulation, multiple ovarian follicles develop, leading to <strong>increased vascular permeability and secretion of vascular endothelial growth factor (VEGF). This results in fluid shifts from the intravascular to the third space, causing ovarian enlargement and subsequent fluid accumulation in the peritoneal and occasionally pleural cavities.</strong></li>\n<li>Manifestations vary from mild abdominal discomfort and bloating to severe ascites, oliguria, electrolyte imbalances, and respiratory distress.</li>\n<li>OHSS is categorised into mild, moderate, and severe forms based on clinical findings and the need for medical intervention.</li>\n<li><strong>Management</strong> involves symptomatic treatment for mild cases, including oral fluids and analgesia.\n<ul>\n<li>Moderate to severe cases may necessitate hospitalisation for intravenous fluids, electrolyte replacement, monitoring of renal function, and occasionally paracentesis or thoracentesis for symptomatic relief.</li>\n<li>Severe cases may require cessation of gonadotropin therapy and postponement of embryo transfer.</li>\n<li>Cabergoline is said to decrease VEGF and may be used in the prevention of OHSS.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Bone marrow depression (Option A):</strong> This is not a known adverse effect of clomiphene citrate. Bone marrow suppression is unrelated to ovulation induction.</p>\n<p><strong>Secondary amenorrhea (Option C):</strong> Clomiphene is used to <strong>treat</strong> amenorrhea (anovulation) rather than cause it.</p>\n<p><strong>Multiple pregnancy (Option D):</strong> Clomiphene increases the risk of multiple pregnancies (twins or higher-order multiples), but this is not the <strong>most serious</strong> complication. The correct answer remains OHSS due to its life-threatening potential.</p>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">LDL</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Cholesterol</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">VLDL </span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Triglycerides</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Estrogen replacement for postmenopausal symptoms causes an increase in:</span></p>",
      "unique_key": "DT1188892",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188892,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Estrogen causes:</strong></p>\n<ul>\n<li><strong>Decreases Plasma LDL (Option A)</strong></li>\n<li><strong>Decreases Cholesterol (Option B)</strong></li>\n<li>Plasma HDL Increases</li>\n<li><strong>Triglycerides increase</strong></li>\n<li><strong>VLDL is not significantly increased</strong> by estrogen therapy <strong>(Option C)</strong></li>\n<li>There is an increased HDL = LDL ratio, which is probably responsible for the rarity of atherosclerosis in premenopausal women.</li>\n<li>It also increases blood coagulability by inducing the formation of clotting factors.</li>\n<li>Estrogen increases the lithogenicity of bile.</li>\n</ul>\n<p><strong>Progesterone causes:</strong></p>\n<ul>\n<li>Plasma LDL increases</li>\n<li>Decreases HDL</li>\n</ul>",
      "correct_choice_id": 74,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduces fracture rates</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Avoids endometrial hyperplasia</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduces the incidence of venous thrombosis</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">No increase in incidence of breast carcinoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The advantages of using Raloxifene over estrogen in postmenopausal women are all of the following:</span></p>",
      "unique_key": "DT1188899",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188899,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation for answer</strong>:</p>\n<ul>\n<li><strong>Raloxifene</strong> is a <strong>Selective Estrogen Receptor Modulator (SERM)</strong> used in the management of postmenopausal osteoporosis.</li>\n<li>Unlike estrogen, <strong>raloxifene does not reduce the risk of venous thrombosis</strong>. In fact, like estrogen, it may increase the risk of venous thromboembolism.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Reduces fracture rates (Option A):</strong> Raloxifene, like estrogen, helps prevent osteoporosis and reduces fracture risk in postmenopausal women.</p>\n<p><strong>Avoids endometrial hyperplasia (Option B):</strong> Raloxifene does <strong>not stimulate the endometrium</strong>, thereby reducing the risk of endometrial hyperplasia, unlike unopposed estrogen.</p>\n<p><strong>No increase in incidence of breast carcinoma (Option D):</strong> Raloxifene does <strong>not increase the risk of breast cancer</strong>, which is an advantage over estrogen therapy.</p>",
      "correct_choice_id": 83,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Thrombosis</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Fibrocystic disease</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Fibroadenoma</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Haemorrhage</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Hormone replacement therapy has, absolute contraindication:</span></p>",
      "unique_key": "DT1188904",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188904,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The most important absolute contraindication to<strong> hormone replacement therapy (HRT) i</strong>s the presence of<strong> active or past thrombosis (deep vein thrombosis, pulmonary embolism, or other thromboembolic disorders).</strong></li>\n</ul>\n<p>Contraindications are:</p>\n<p>A = <strong>A</strong>ctive liver disease</p>\n<p>B = Undiagnosed vaginal <strong>B</strong>leeding</p>\n<p>C = <strong>C</strong>ancers: endometrial/breast</p>\n<p>D = <strong>D</strong>VT</p>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Fibrocystic disease (Option B):</strong> Benign breast conditions like fibrocystic changes are not absolute contraindications to HRT.</p>\n<p><strong>Fibroadenoma (Option C):</strong> Fibroadenoma is a benign breast lesion and does not contraindicate the use of HRT.</p>\n<p><strong>Haemorrhage (Option D):</strong> While unexplained vaginal bleeding is a <strong>relative contraindication</strong> requiring evaluation before initiating HRT, it is not an absolute contraindication like thrombosis.</p>",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">10 pg/mL</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">20 pg/mL</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">30 pg/mL</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">40 pg/mL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The cut-off point of serum estrogen level for the diagnosis of ovarian failure:</span></p>",
      "unique_key": "DT1188939",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188939,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Diagnosis of menopause or ovarian failure </strong>is made from the classical symptom of <strong>hot flush (50%)</strong> confirmed by <strong>elevated FSH levels to more than 40 IU/mL</strong> and <strong>serum estradiol &lt; 20 pg/mL.</strong></li>\n<li>This low level of estrogen reflects the cessation of ovarian follicular activity.</li>\n</ul>",
      "correct_choice_id": 102,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Progesterone</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Estrogen and progesterone</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Estrogen</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">None</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 46-year-old female suffering from severe menorrhagia underwent hysterectomy 6 years ago. She wishes to take hormone replacement therapy. I/V/O hot flushes and atrophic vaginitis. The treatment of choice is:</span></p>",
      "unique_key": "DT1188940",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188940,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Both <strong>estrogen alone and estrogen + progesterone</strong> can be used for treating menopausal symptoms.</li>\n<li><strong>Progesterone </strong>alone is not a treatment option. <strong>(Option A ruled out)</strong></li>\n</ul>\n<p>The choice depends on whether the uterus is present or not:</p>\n<ul>\n<li><strong>Uterus absent</strong> - <strong>Estrogen</strong> alone can be given as HRT</li>\n<li>For women with a uterus, a progestin should be combined with an estrogen to lower the risk of endometrial cancer.</li>\n<li>All women who have an <strong>intact uterus</strong> should receive combined <strong>estrogen-progesterone</strong><strong> therapy. (Option B ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">SSRI</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Progesterone</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Oestrogen</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Anxiolytics</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 26-year-old woman presents to the outpatient clinic with complaints of mood swings, irritability, breast tenderness, and bloating that recur about a week before her periods and resolve shortly after menstruation begins. These symptoms have been present for the past 6 months and significantly interfere with her work and social life. Her cycles are regular. A menstrual diary confirms the cyclical nature of symptoms. She is otherwise healthy and does not wish to use hormonal contraception at this time.<br>Which of the following treatment options has shown the best evidence-based result for relieving her symptoms?</span></p>",
      "unique_key": "DT1188945",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188945,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Frequently, women of reproductive age experience symptoms during the late luteal phase of their menstrual cycle, and collectively these complaints are termed <strong>premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD)</strong></li>\n<li>It is mostly seen in women aged 30-45 years</li>\n<li><strong>SSRIs</strong>, such as <strong>fluoxetine</strong>, have shown effectiveness in treating premenstrual syndrome (PMS) by modulating <strong>serotonin 56 levels</strong>.</li>\n<li>They can help <strong>alleviate mood and physical symptoms associated with PMS</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Progesterone (Option B)</strong>: While hormonal therapies may be considered, the evidence for progesterone alone in treating PMS is not as robust.</p>\n<p><strong>Oestrogen (Option C)</strong>: Estrogen is not typically used as a standalone therapy for PMS.</p>\n<p><strong>Anxiolytics (Option D):</strong> Anxiolytics may help with specific symptoms, but they are not the primary modality for managing PMS.</p>",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Endometriosis</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Dysmenorrhea</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Pelvic tuberculosis</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Mittelschmerz</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 19-year-old woman gives a history of sharp pain in the lower abdomen for 2 days every month, approximately 2 weeks before the menses. The most probable aetiology for her pain is:</span></p>",
      "unique_key": "DT1188948",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188948,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>A female giving a history of <strong>sharp pain in the lower abdomen,</strong> every month, 2 weeks before menstruation, suggests <strong>mittelschmerz</strong> as the diagnosis.</li>\n<li>Mittelschmerz is synonymous with painful ovulation. Pain is associated with the rupture of the ovarian follicle at the time of ovulation.</li>\n<li>It typically presents as <strong>sharp or colicky unilateral lower abdominal pain</strong> lasting for <strong>a few hours to 2 days</strong>, occurring <strong>about 14 days before menstruation</strong>.</li>\n<li>The condition is <strong>self-limiting</strong> and usually requires <strong>no specific treatment</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Endometriosis (Option A):</strong> Typically presents with chronic pelvic pain, dysmenorrhea, and dyspareunia. Pain is usually progressive and associated with menstruation, not ovulation.</p>\n<p><strong>Dysmenorrhea (Option B):</strong> Refers to crampy lower abdominal pain associated with menstruation, not mid-cycle. It usually begins a few hours before or at the onset of menses.</p>\n<p><strong>Pelvic tuberculosis (Option C):</strong> Often presents with chronic pelvic pain, infertility, or menstrual irregularities. Mid-cycle pain alone is not characteristic.</p>",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Bromocriptine</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Ibuprofen</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Mefenamic acid</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Norethisterone and ethinyl estradiol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All are used in treating spasmodic dysmenorrhea except:</span></p>",
      "unique_key": "DT1188953",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188953,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Bromocriptine</strong>, a dopamine agonist, is not used in the treatment of primary dysmenorrhea and is used instead in hyperprolactinemia and prolactinomas.</li>\n<li><strong>Spasmodic dysmenorrhoea</strong> is another name for <strong>primary dysmenorrhoea</strong>.</li>\n<li>The aetiology of primary dysmenorrhea includes an <strong>excessive amount of prostanoids secreted from the endometrium during menstruation</strong>.</li>\n<li>The prostanoids result in <strong>increased uterine contractions with a dysrhythmic pattern, increased basal tone, and increased active pressure.</strong></li>\n<li>Pain is spasmodic. Pain of primary dysmenorrhea usually begins a <strong>few hours before or just after the onset of a menstrual period and may last 48 to 72 hours.</strong></li>\n</ul>\n<p><strong>Characteristics of spasmodic dysmenorrhoea</strong></p>\n<ul>\n<li>Seen in adolescent girls</li>\n<li>Pain begins a few hours before the rest of menstruation and lasts for 12-24 hours, but never more than 48 hours.</li>\n<li><strong>Management</strong>: <strong>NSAIDs (like ibuprofen and mefenamic acid), OCPs (Norethisterone and ethinyl estradiol) can be used for management. (Options B, C and D ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 141,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Tuberculosis</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Adenomyosis</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">CIN</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Endometriosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 24-year-old woman presents with complaints of progressively worsening lower abdominal pain that begins 1-2 days before menstruation and continues during the periods. The pain is described as deep, dull, and associated with dyspareunia and dyschezia. She attained menarche at 13 years and has had regular menstrual cycles. On pelvic examination, the uterus feels fixed and tender in the posterior fornix.<br>Which of the following is least likely to be a cause of her condition?</span></p>",
      "unique_key": "DT1188957",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188957,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The most likely diagnosis is <strong>secondary dysmenorrhoea</strong>.</li>\n<li><strong>Cervical intraepithelial neoplasia (CIN)</strong> is <strong>least likely</strong> to cause dysmenorrhoea. CIN is a <strong>premalignant cervical lesion</strong> and does not typically present with menstrual pain or associated features like a fixed uterus or deep dyspareunia.</li>\n</ul>\n<p><strong>Causes of secondary dysmenorrhea</strong>:</p>\n<ul>\n<li>PID</li>\n<li><strong>Endometriosis (Option B ruled out)</strong></li>\n<li><strong>Adenomyosis (Option D ruled out)</strong></li>\n<li>IUCD</li>\n<li>Uterine fibroid</li>\n<li>Polyps</li>\n<li>Cervical stenosis</li>\n<li>Congenital malformation of the uterus, like a bicornuate uterus.</li>\n<li><strong>Genital tuberculosis</strong> is an important cause of <strong>chronic pelvic pain</strong> and <strong>secondary dysmenorrhoea</strong> in endemic regions. <strong>(Option C ruled out)</strong></li>\n</ul>\n<p><strong>Management</strong>: Treatment of the underlying cause.</p>",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Most common in nullipara</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Characterised by the growth of the endometrium outside the uterus</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Presents with menorrhagia, dysmenorrhea, and an enlarged uterus</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">More common in young women</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 38-year-old multiparous woman presents with complaints of heavy menstrual bleeding and progressively worsening lower abdominal pain over the last 6 months. Her cycles are regular but associated with severe dysmenorrhea and passage of clots. On pelvic examination, the uterus is found to be uniformly enlarged, boggy, and tender. Transvaginal ultrasound suggests a globular uterus with heterogeneous myometrial echotexture.<br>Which of the following statements is true regarding the likely diagnosis?</span></p>",
      "unique_key": "DT1188958",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188958,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The most likely diagnosis is <strong>adenomyosis</strong>, a condition where <strong>endometrial tissue is present within the myometrium</strong>.</li>\n<li>It typically presents with:\n<ul>\n<li><strong>Heavy menstrual bleeding (menorrhagia)</strong></li>\n<li><strong>Severe dysmenorrhea</strong></li>\n<li>A <strong>uniformly enlarged, boggy, tender uterus</strong> was found on examination.</li>\n<li><strong>Ultrasound</strong> often reveals a <strong>globular uterus with heterogeneous myometrial echotexture</strong>.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Most common in nullipara (Option A): </strong>Adenomyosis is more commonly seen in <strong>parous</strong> women, not nulliparous women.</p>\n<p><strong>Growth of the endometrium outside the uterus (Option B): </strong>This describes <strong>endometriosis</strong>, not adenomyosis.</p>\n<p><strong>More common in young women (Option D): </strong>Adenomyosis is typically seen in <strong>women over 35 years</strong>, especially those with a history of childbirth.<br /> </p>",
      "correct_choice_id": 163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Cardiovascular disease</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteoporosis</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Hot flushes</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Atrophic vaginitis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Hormone replacement therapy (HRT) is indicated in all except:</span></p>",
      "unique_key": "DT1280046",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280046,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>HRT is not recommended for the prevention of cardiovascular disease</strong>.</li>\n<li>Large clinical trials, including the <strong>Women's Health Initiative (WHI)</strong>, have demonstrated that HRT may increase the risk of <strong>cardiovascular events</strong> such as <strong>coronary heart disease (CHD)</strong> and <strong>stroke</strong>, particularly when started in older postmenopausal women.</li>\n<li>Hormone Replacement Therapy (HRT) is generally indicated for the management of <strong>vasomotor symptoms (hot flushes), urogenital atrophy (atrophic vaginitis), and prevention of osteoporosis</strong> in postmenopausal women. <strong>(Options B, C and D ruled out)</strong></li>\n<li>HRT doesn't increase the risk of <strong>Ca Cervix</strong>; it is <strong>OCP that increases the risk of Ca Cervix</strong></li>\n</ul>",
      "correct_choice_id": 171,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}